loader

Caribou Biosciences Inc.

NASDAQ:CRBU
1 min read

Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel , an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology Annual Meeting

Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences

Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.

Latest News

More News

Latest News

Outlook Reports world

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES